Breast cancer with BRCA1/2 mutations is emerging as a distinctive group of breast cancers that present at an earlier age with hallmarks of genomic instability and accumulation of DNA damage.1, 2, 3 Two poly (ADP-ribose) polymerase inhibitors (PARPi) are available as the therapeutic option (olaparib and talazoparib), but many patients do not derive benefit because of multiple primary and secondary resistance mechanisms and toxicities.4 Here, BRCA1 is linked to breast carcinoma.